Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Ozempic can slow gallbladder emptying and accelerate weight loss, increasing the risk of bile stasis, gallstones, and biliary colic that may require dietary changes, medication adjustments, or cholecystectomy. Persistent right upper quadrant pain, nausea, fever, or jaundice warrants imaging and a tailored treatment plan based on your diabetes and gallbladder risk profile.
There are several factors to consider in deciding whether to continue or switch medications; see below for more important details before making any changes.
Semaglutide (brand name Ozempic) has become a popular prescription for type 2 diabetes management and weight loss. Yet some people report right-upper-abdominal discomfort or full-blown gallbladder attacks after starting it. If you're asking, "why does Ozempic cause gallbladder pain?" here's a balanced look at the evidence, symptoms to watch for, and how to decide whether to stay on your current medication or consider alternatives.
Ozempic belongs to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It helps control blood sugar and contributes to weight loss by:
These actions support metabolic health, but they can also affect the gallbladder in ways that may lead to pain or gallstones.
Several mechanisms likely explain increased gallbladder issues in people taking Ozempic:
Slowed Bile Emptying
GLP-1 RAs can decrease gallbladder contractility. When the gallbladder doesn't empty fully, bile can stagnate, increasing the risk of sludge or stone formation.
Rapid Weight Loss
Losing weight quickly—especially more than 1.5–2 pounds per week—can create supersaturated bile. This raises cholesterol crystal formation and gallstone risk. Ozempic's appetite-suppressing effect accelerates weight loss, so gallstones are more likely.
Altered Biliary Composition
Changes in the hormones that regulate bile salts, cholesterol, and bilirubin can disturb the normal balance, increasing stone formation.
Underlying Risk Factors Amplified
If you're already overweight, female, over age 40, or have a family history of gallstones, Ozempic may tip the balance toward gallbladder trouble.
Not all upper-abdominal discomfort is gallbladder pain, but here's what to look for:
Common biliary colic symptoms
Warning signs of serious complications
If you suspect acute cholecystitis—a serious inflammation of the gallbladder—use Ubie's free AI-powered symptom checker for Acute Cholecystitis to assess your symptoms before seeking care.
If you experience warning-sign symptoms or repeated biliary colic, your healthcare provider may recommend:
Early diagnosis can prevent complications like gallbladder rupture or pancreatitis.
Deciding to switch from Ozempic to another therapy involves weighing benefits and risks:
Factors to consider
Alternative diabetes or weight-loss medications
Before making any change:
Ozempic offers clear advantages in blood-sugar control, cardiovascular protection, and significant weight loss. For many people, these benefits outweigh the gallbladder risks. However, if you develop symptomatic gallstones or repeated biliary colic, a different approach may be best.
Always speak to a doctor about any symptoms that could be life-threatening or serious. Your health is unique, and only a healthcare professional can provide guidance tailored to your needs.
(References)
* Sun, F., Cai, B., Sun, C., Yin, F., & Wu, C. (2023). Risk of cholelithiasis and cholecystitis with glucagon-like peptide-1 receptor agonists: A systematic review and meta-analysis of randomized controlled trials. *Frontiers in Endocrinology*, *14*, 1162395. https://pubmed.ncbi.nlm.nih.gov/37025816/
* Faillie, J. L., Hillaire-Buys, D., & Salvo, F. (2022). Association of Glucagon-like Peptide-1 Receptor Agonist Use With Acute Gallbladder Disease. *JAMA Internal Medicine*, *182*(1), 107-109. https://pubmed.ncbi.nlm.nih.gov/34870637/
* Smits, M. M., & Van Raalte, D. H. (2021). Gallstones and GLP-1 receptor agonists: from common to concerning. *The Lancet Diabetes & Endocrinology*, *9*(7), 406-407. https://pubmed.ncbi.nlm.nih.gov/34089772/
* Nauck, M. A., & Meier, J. J. (2021). Glucagon-like peptide 1 receptor agonists and the risk of acute gallbladder disease: a systematic review and meta-analysis of randomized controlled trials. *The Lancet Diabetes & Endocrinology*, *9*(7), 415-422. https://pubmed.ncbi.nlm.nih.gov/34089774/
* He, L., Wang, J., Wang, R., Meng, S., & Li, R. (2023). Risk of cholelithiasis and cholecystitis associated with GLP-1 receptor agonists: a systematic review and meta-analysis. *Frontiers in Pharmacology*, *14*, 1139474. https://pubmed.ncbi.nlm.nih.gov/36936357/
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.